Bayer gains key FDA expansion for fast-rising prostate cancer drug Nubeqa
4th June 2025 Uncategorised 0Bayer has taken another step toward achieving its €3 billion peak sales estimate for androgen receptor inhibitor Nubeqa, scoring an FDA approval to expand its use to all patients with metastatic castration-sensitive prostate cancer, with or without added chemotherapy.
More: Bayer gains key FDA expansion for fast-rising prostate cancer drug Nubeqa
Source: fierce